Is Palbociclib a cost-effective strategy in the second-line treatment of metastatic breast cancer in Iran?

CONCLUSIONS: The 'Iranian Palbociclib + Fulvestrant' combination was cost-effective in second-line therapy for HR+ HER2- MBC in Iran.PMID:37768209 | DOI:10.1080/14737167.2023.2263167

Source: Expert Review of Pharmacoeconomics and Outcomes Research - September 28, 2023 Category: Health Management Authors: Ali Darvishi Ramin Abdi Dezfouli Aliakbar Fazaeli Rajabali Daroudi Narges Zandieh Source Type: research